Selective oestrogen receptor modulators/new antioestrogens: A clinical perspective

Cancer Treatment Reviews

Volumn 30, Issue 8, 2004, Pages 695-706

  Robertson, John F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Antioestrogen; Breast cancer; Fulvestrant; Selective oestrogen receptor modulator

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; 21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; DIETHYLSTILBESTROL; DROLOXIFENE; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; EXEMESTANE; FULVESTRANT; IDOXIFENE; LETROZOLE; MEGESTROL ACETATE; METHYLTRIPHENYLETHYLENE; NAFOXIDINE; NEW DRUG; PIPENDOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; TRIPHENYLCHLORETHYLENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 191703;

ADVANCED CANCER; ANOREXIA; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CROSS RESISTANCE; DEPRESSION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TOLERABILITY; DYSLIPIDEMIA; EDEMA; ENDOMETRIUM CANCER; ESTROGEN THERAPY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GYNECOLOGIC DISEASE; HEADACHE; HOT FLUSH; HUMAN; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PAIN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRURITUS; SWEAT GLAND DISEASE; THROMBOEMBOLISM; URINARY TRACT INFECTION; UTERUS; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA DISEASE; VAGINITIS; VASCULAR DISEASE; VASODILATATION; VOMITING; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOPREVENTION; CLINICAL TRIALS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 8644260921     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2004.04.003     Document Type: Article

References (69)

1. Jordan VC. Why tamoxifen? In: Jordan VC, editor. Tamoxifen: A guide for clinicians and patients. Huntington, NY; 1996. 15-23
2. Howell A. Johnston S.R.D. Selective estrogen receptor modulators (SERMs) In: Robertson J.F.R. Nicholson R.I. Hayes D.F. (Eds.) Endocrine therapy of breast cancer 2002 45-62 Martin Dunitz London
3. Sherwin B.B. Estrogen and cognitive aging in women Trends Pharmacol. Sci. 23 2002 527-534
4. Cavailles V. Estrogens and receptors: An evolving concept Climacteric 5 Suppl 2 2002 20-26
5. Lippman M. Monaco M.E. Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture Cancer Res. 37 1977 1901-1907
6. Margolese R.G. Fisher B. Hortobagyi G.N. Bloomer W.D. Neoplasms of the breast In: Bast R.C. Kufe D.W. Pollock R.E. Weichselbaum R.R. Holland J.F. Frei III E. (Eds.) Cancer medicine vol. 5 2000 1735-1822 BC Decker Hamilton
7. Beatson G.T. On the treatment of inoperable cases of carcinogen of the mamma: Suggestions for a new method of treatment, with illustrative cases Lancet 2 1896 105-107
8. Haddow A. Watkinson J.M. Paterson E. Influence of synthetic oestrogens upon advanced malignant disease BMJ 2 1944 393-398
9. Bertelli G. Pronzato P. Amoroso D. et al. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels Breast Cancer Res. Treat. 12 1988 307-310
10. Powles T.J. Hickish T. Kanis J.A. Tidy A. Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women J. Clin. Oncol. 14 1996 78-84
11. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet1998;351:1451-67
12. Fisher B. Costantino J.P. Redmond C.K. Fisher E.R. Wickerham D.L. Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer Inst. 86 1994 527-537
13. Robinson S.P. Parker C.J. Jordan V.C. Preclinical studies with toremifene as an antitumor agent Breast Cancer Res. Treat. 16 Suppl 1990 S9-S17
14. Hasmann M. Rattel B. Loser R. Preclinical data for droloxifene Cancer Lett. 84 1994 101-116
15. Johnston S.R. Riddler S. Haynes B.P. et al. The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance Br. J. Cancer 75 1997 804-809
16. Tomas E. Kauppila A. Blanco G. Apaja-Sarkkinen M. Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients Gynecol. Oncol. 59 1995 261-266
17. Marttunen M.B. Hietanen P. Tiitinen A. Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients J. Clin. Endocrinol. Metab. 83 1998 1158-1162
18. Wiseman L.R. Goa K.L. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer Drugs 54 1997 141-160
19. Stenbygaard L.E. Herrstedt J. Thomsen J.F. Svendsen K.R. Engelholm S.A. Dombernowsky P. Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial Breast Cancer Res. Treat. 25 1993 57-63
20. Vogel C.L. Shemano I. Schoenfelder J. Gams R.A. Green M.R. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer J. Clin. Oncol. 11 1993 345-350
21. Pyrhonen S. Valavaara R. Vuorinen J. Hajba A. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment Breast Cancer Res. Treat. 29 1994 223-228
22. Pyrhonen S. Valavaara R. Modig H. et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: A randomized double-blind, the 'nordic' phase III study Br. J. Cancer 76 1997 270-277
23. Hayes D.F. Van Zyl J.A. Hacking A. et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer J. Clin. Oncol. 13 1995 2556-2566
24. Gershanovich M. Garin A. Baltina D. Kurvet A. Kangas L. Ellmen J. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group Breast Cancer Res. Treat. 45 1997 251-262
25. Nomura Y. Tominaga T. Abe O. Izuo M. Ogawa N. Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer - a comparative study by a double blind method with tamoxifen Gan To Kagaku Ryoho 20 1993 247-258
26. Milla-Santos A. Milla L. Rallo L. Solano V. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer Breast Cancer Res. Treat. 65 2001 119-124
27. Pyrhonen S. Ellmen J. Vuorinen J. et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer Breast Cancer Res. Treat. 56 1999 133-143
28. Holli K. Valavaara R. Blanco G. et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group J. Clin. Oncol. 18 2000 3487-3494
29. Ke H.Z. Chen H.K. Qi H. et al. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats Bone 17 1995 491-496
30. Loser R. Seibel K. Roos W. Eppenberger U. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen Eur. J. Cancer Clin. Oncol. 21 1985 985-990
31. Haarstad H. Gundersen S. Wist E. Raabe N. Mella O. Kvinnsland S. Droloxifene - a new anti-estrogen. A phase II study in advanced breast cancer Acta Oncol. 31 1992 425-428
32. Buzdar A. Hayes D. El-Khoudary A. et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer Breast Cancer Res. Treat. 73 2002 161-175
33. Nuttall M.E. Bradbeer J.N. Stroup G.B. et al. Idoxifene: A novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats Endocrinology 139 1998 5224-5234
34. Coombes R.C. Haynes B.P. Dowsett M. et al. Idoxifene: Report of a phase I study in patients with metastatic breast cancer Cancer Res. 55 1995 1070-1074
35. Lee E.S. Schafer J.M. Yao K. et al. Cross resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice Clin. Cancer Res. 6 2000 4893-4899
36. Johnston S.R. Gorbunova V. Lichinitser M. et al. A multicentre double-blind randomised phase III trial of idoxifene versus tamoxifen as first-line endocrine therapy for metastatic breast cancer Proc. Am. Soc. Clin. Oncol. 20 2001 29a
37. Sato M. Turner C.H. Wang T. Adrian M.D. Rowley E. Bryant H.U. LY353381.HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo J. Pharmacol. Exp. Ther. 287 1998 1-7
38. Munster P.N. Buzdar A. Dhingra K. et al. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer J. Clin. Oncol. 19 2001 2002-2009
39. Buzdar A.U. O'Shaughnessy J. Hudis C. et al. Preliminary results of a randomized double-blind phase II study of the selective estrogen receptor modulator (SERM) arzoxifene in patients with locally advanced or metastatic breast cancer Proc. Am. Soc. Clin. Oncol. 20 2001 45a
40. Black L.J. Jones C.D. Clark J.H. Clemens J.A. LY156758: A unique antiestrogen displaying high affinity for estrogen receptors, negligible estrogenic activity and near-total estrogen antagonism in vivo Breast Cancer Res. Treat. 2 1982 279
41. Buzdar A.U. Marcus C. Holmes F. Phase II evaluation of LY156758 in metastatic breast cancer Oncology 45 1988 344-345
42. Gradishar W.J. Glusman J.E. Vogel C. et al. Raloxifene HCI, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer Breast Cancer Res. Treat. 46 1 1997 [abstract 209]
43. Delmas P.D. Bjarnason N.H. Mitlak B.H. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N. Engl. J. Med. 337 1997 1641-1647
44. Cauley J.A. Norton L. Lippman M.E. et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res. Treat. 65 2001 125-134
45. Jubelirer S.J. Crowell E.B. Jr. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia W V Med. J. 96 2000 602-604
46. Cotreau M.M. Stonis L. Dykstra K.H. et al. Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women J. Clin. Pharmacol. 42 2002 157-165
47. Lønning P.E. Taylor P.D. Anker G. et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy Breast Cancer Res. Treat. 67 2001 111-116
48. Peethambaram P.P. Ingle J.N. Suman V.J. Hartmann L.C. Loprinzi C.L. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis Breast Cancer Res. Treat. 54 1999 117-122
49. Beex L. Pieters G. Smals A. Koenders A. Benraad T. Kloppenborg P. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer Cancer Treat. Rep. 65 1981 179-185
50. Ingle J.N. Ahmann D.L. Green S.J. et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer N. Engl. J. Med. 304 1981 16-21
51. Heuson J.C. Engelsman E. Blonk-Van Der Wijst J. et al. Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: An EORTC study Br. Med. J. 2 1975 711-713
52. Matelski H. Greene R. Huberman M. Lokich J. Zipoli T. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer Am. J. Clin. Oncol. 8 1985 128-133
53. Stewart H.J. Forrest A.P. Gunn J.M. et al. The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer Eur. J. Cancer Suppl 1 1980 83-88
54. Wakeling A.E. Dukes M. Bowler J. A potent specific pure antiestrogen with clinical potential Cancer Res. 51 1991 3867-3873
55. Addo S. Yates R.A. Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers Br. J. Cancer 87 2002 1354-1359
56. Howell A. Osborne C.K. Morris C. Wakeling A.E. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen Cancer 89 2000 817-825
57. Howell A. DeFriend D.J. Robertson J.F. et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer Br. J. Cancer 74 1996 300-308
58. Howell A. Robertson J.F.R. Quaresma Albano J. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J. Clin. Oncol. 20 2002 3396-3403
59. Osborne C.K. Pippen J. Jones S.E. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial J. Clin. Oncol. 20 2002 3386-3395
60. Robertson J.F.R. Osborne C.K. Howell A. et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials Cancer 98 2003 229-238
61. Robertson J.F.R. Howell A. Abram P. Lichinitser M. Elledge R. Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women Ann. Oncol. 13 Suppl 5 2002 46 [abstract 164O]
62. Howell A. Robertson J.F.R. Sensitivity to endocrine therapy is maintained in both fulvestrant- and tamoxifen-treated postmenopausal women with advanced breast cancer Ann. Oncol. 13 Suppl 5 2002 46 [abstract 173P]
63. Nabholtz J.M. Buzdar A. Pollak M. et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group J. Clin. Oncol. 18 2000 3758-3767
64. Mouridsen H. Gershanovich M. Sun Y. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group J. Clin. Oncol. 19 2001 2596-2606
65. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359:2131-39
66. Buzdar A. The ATAC ('Arimidex', tamoxifen, alone or in combination) trial in postmenopausal women with early breast cancer - updated efficacy results based on a median follow-up of 47 months Breast Cancer Res. Treat. 77 2003 295
67. Dardes R.C. O'Regan R.M. Gajdos C. et al. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo Clin. Cancer Res. 8 2002 1995-2001
68. Yamamoto N. Wada O. Yanagisawa J. A novel antiestrogen, TAS-108 (SR 16234) shows full antagonist activity to ER alpha and beta with a unique mechanism Eur. J. Cancer 39 Suppl 3 2002 S96
69. Johnston S.R. Acquired tamoxifen resistance in human breast cancer - potential mechanisms and clinical implications Anticancer Drugs 8 1997 911-930